FDA opens door to multiarm, multicompany clinical trials

FDA opens door to multiarm, multicompany clinical trials

One of the best things that can happen to clinical trials is to make the process smoother. That is exactly what the FDA is trying to do. They have outlined how developers of drugs targeting rare pediatric diseases to streamline their clinical development programs and...